New Zealand switched from oral polio vaccine (OPV) to inactivated polio vaccine (IPV) in 2002 (see Appendix 1).
Other polio-containing vaccines registered (approved for use) and available (marketed) in New Zealand are:
OPV is no longer used in New Zealand. OPV continues to be used in many countries because it remains the vaccine for the WHO Expanded Programme on Immunization, but the WHO plans to withdraw this vaccine worldwide by 2019/201 (see section 16.3.2).
See also section 14.4.2 for information about DTaP-IPV-HepB/Hib vaccine.
Virtually all infants will seroconvert after three doses of IPV vaccine, and more than 85 percent will seroconvert after two doses. The efﬁcacy of IPV is greater than 90 percent.6
The combined IPV-containing vaccines induce immune responses against polioviruses superior to IPV stand-alone vaccines. This is due to the effect of the aluminium adjuvant present in these combination vaccines.6
Available data indicates the persistence of antibodies up to school age, following two or three doses of IPV-containing vaccine in the ﬁrst year of life and a booster in the second year. There is no data beyond this because a preschool booster is given at this time. There is a strong anamnestic response to this preschool booster and it is expected to confer long-term protection, possibly lifelong.6
Transport according to the National Guidelines for Vaccine Storage and Distribution.7 Store at +2oC to +8oC. Do not freeze.
DTaP-IPV-HepB/Hib vaccine should be stored in the dark.
The dose of DTaP-IPV-HepB/Hib (Infanrix-hexa) and DTaP-IPV (Infanrix-IPV) is 0.5 mL, administered by intramuscular injection (see section 2.3).
The dose of monovalent IPV (IPOL) is 0.5 mL, administered by subcutaneous injection (see section 2.3).
DTaP-IPV-HepB/Hib, DTaP-IPV and IPV may be given at the same time as inactivated or live attenuated vaccines, at separate sites and in separate syringes. (See also section 14.4.4 for information about co-administration of DTaP-IPV-HepB/Hib and PCV13.)